Why the study?
Do pharmacologic therapies improve walking distance and symptoms in patients with intermittent claudication?
Population
Peripheral arterial disease patients with intermittent claudication
Design
Review
Authors
Loading...
May support cilostazol when supervised exercise unavailable; leaves open need for head-to-head RCTs.
Do pharmacologic therapies improve walking distance and symptoms in patients with intermittent claudication?
Cilostazol is highlighted as the most beneficial pharmacologic agent for improving walking distance and quality of life in patients with intermittent claudication when supervised exercise is unavailable.
Steven M. Dean (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: